In this video, Xiuning Le, MD, PhD, discusses how she approaches putting together a treatment plan for a patient with EGFR-mutated lung cancer.

EMA committee recommends extension of marketing authorisation for Janssen-Cilag’s subcutaneous Rybrevant to treat advanced EGFR-mutated NSCLC: Beerse, Belgium Tuesday, February ...

The molecular basis and mechanisms of action of combining classic cytotoxic agents (e.g. platinum-containing drugs, taxanes, etc.) and novel agents (e.g. tirapazamine, EGFR inhibitors and other ...

the improvement in quality of life and the assurance of drug exposure, considering that 30–41% of patients with EGFR mutations randomly assigned to first-line chemotherapy in randomized clinical ...

Previously, EGFR mutation-positive NSCLC patients relied ... Both trials linked the drug's chemo combo to longer life expectancy and progression-free survival time compared with chemo alone.

Tagrisso has been recommended as an adjuvant therapy following complete surgical resection in adults with stage 1B to 3A non-small cell lung cancer (NSCLC) whose tumours have epidermal growth factor ...

in which treatment with the drug after surgery reduced the relative risk of disease recurrence or death by 83% compared to placebo in patients with stage 2 to 3A EGFR-mutated NSCLC. Survival without ...

Welcome to the AbbVie fourth-quarter 2024 Earnings Conference Call. [Operator instructions] Today's call is also being recorded. If you have any objections, you may disconnect at this time. I would ...

In England, about 600 people will benefit from the daily pill that helps treat lung cancer as it becomes routinely available on the NHS.